In the news release, Protagonist Therapeutics to Present at the
Cantor Fitzgerald Global Healthcare Conference, issued 11-Sep-2017 by Protagonist Therapeutics, Inc.
over PR Newswire, we are advised by the company that the first
paragraph, first sentence, should read "Tuesday, September 26 from 8:35-9:05 AM in Grand Ballroom 1" rather than
"September 26 from 9:45 - 10:15 am ET" as originally issued
inadvertently. The complete, corrected release follows:
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global
Healthcare Conference
MILPITAS, Calif., Sept. 11, 2017 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the Company's President
and Chief Executive Officer, will provide a corporate overview at
the Cantor Fitzgerald Global Healthcare Conference on Tuesday,
September 26 from 8:35-9:05 AM in
Grand Ballroom 1. The conference is being held at the
InterContinental New York Barclay Hotel in New York, NY.
A live and archived audio webcast of the presentation can be
accessed by visiting the Investors page of Protagonist Therapeutics
corporate website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics
Protagonist
Therapeutics is a clinical development-stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to address significant unmet
medical needs. Its primary focus is on developing potential
first-in-class oral targeted therapy-based peptide drugs that work
by blocking biological pathways that are currently targeted by
marketed injectable antibody drugs. Lead peptide candidates,
PTG-100 and PTG-200, are based on this approach. PTG-100 is
currently in Phase 2b clinical trials for moderate-to-severe
ulcerative colitis, and the company plans to initiate clinical
trials of PTG-200 in 2017 as a potential treatment for Crohn's
disease. The company recently entered into a worldwide
collaboration with Janssen Biotech to co-develop and commercialize
PTG-200. Protagonist is also developing an injectable
hepcidin mimetic, PTG-300, for the treatment of rare diseases such
as beta-thalassemia, currently in a Phase 1 clinical trial.
Protagonist is headquartered in Newark, California with pre-clinical and
clinical staff in California, and
discovery operations both in California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300517245.html
SOURCE Protagonist Therapeutics, Inc.